IGI Laboratories, Inc. (IG) said it has submitted an additional abbreviated new drug application, or ANDA, to the FDA, bringing the company's total number of submissions to six.
IGI President and CEO Charlie Moore commented, "Our team has done a tremendous job in effectively managing our development projects. We have built a strong development group, and the team now has six ANDA filings with the US FDA.
We expect to file three-to-five additional ANDAs in 2012, which will bring our total of ANDA submissions to nine to eleven by the end of 2012." The development of ANDA products has successfully been integrated into the company's ongoing contract services business.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.